Kinnate Biopharma Inc. (NASDAQ:KNTE – Get Rating) – Equities researchers at SVB Leerink boosted their FY2026 earnings per share estimates for Kinnate Biopharma in a report released on Thursday, March 16th. SVB Leerink analyst A. Berens now anticipates that the company will earn $0.47 per share for the year, up from their prior forecast of $0.45. The consensus estimate for Kinnate Biopharma’s current full-year earnings is ($3.09) per share.
A number of other research analysts have also commented on the company. Wedbush cut their price target on Kinnate Biopharma from $29.00 to $25.00 and set an “outperform” rating for the company in a report on Thursday. Stifel Nicolaus cut their price target on Kinnate Biopharma from $11.00 to $8.00 and set a “hold” rating for the company in a report on Thursday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Kinnate Biopharma has a consensus rating of “Moderate Buy” and a consensus price target of $25.00.
Kinnate Biopharma Stock Down 0.7 %
Kinnate Biopharma (NASDAQ:KNTE – Get Rating) last announced its earnings results on Wednesday, March 15th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.02).
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of KNTE. FMR LLC raised its stake in shares of Kinnate Biopharma by 51.9% in the second quarter. FMR LLC now owns 2,193,316 shares of the company’s stock valued at $27,658,000 after purchasing an additional 749,012 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Kinnate Biopharma by 209.5% in the second quarter. Goldman Sachs Group Inc. now owns 210,958 shares of the company’s stock valued at $2,660,000 after acquiring an additional 142,804 shares during the period. Western Standard LLC bought a new stake in Kinnate Biopharma in the second quarter valued at $1,296,000. DAFNA Capital Management LLC grew its position in Kinnate Biopharma by 51.5% in the second quarter. DAFNA Capital Management LLC now owns 224,451 shares of the company’s stock valued at $2,830,000 after acquiring an additional 76,300 shares during the period. Finally, Renaissance Technologies LLC grew its position in Kinnate Biopharma by 300.0% in the second quarter. Renaissance Technologies LLC now owns 95,600 shares of the company’s stock valued at $1,206,000 after acquiring an additional 71,700 shares during the period. 98.68% of the stock is currently owned by institutional investors and hedge funds.
Kinnate Biopharma Company Profile
Kinnate Biopharma Inc, a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.
- Get a free copy of the StockNews.com research report on Kinnate Biopharma (KNTE)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Kinnate Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kinnate Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.